{"id":5513,"date":"2016-07-29T22:21:49","date_gmt":"2016-07-29T22:21:49","guid":{"rendered":"https:\/\/www.olartemoure.com\/web\/en\/om-weekly-digest-29-07-2016\/"},"modified":"2017-04-26T14:25:07","modified_gmt":"2017-04-26T14:25:07","slug":"om-weekly-digest-29-07-2016","status":"publish","type":"post","link":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/","title":{"rendered":"OM Weekly Digest (29-07-2016)"},"content":{"rendered":"<p><img decoding=\"async\" class=\"aligncenter size-full wp-image-6258\" src=\"https:\/\/www.olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01.jpg\" alt=\"\" width=\"800\" height=\"108\" srcset=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01.jpg 800w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-300x41.jpg 300w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-768x104.jpg 768w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-461x62.jpg 461w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-260x35.jpg 260w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-50x7.jpg 50w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-150x20.jpg 150w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n<h3 style=\"text-align: center;\"><strong><u>COLOMBIA\u00a0| Patents, Regulatory\u00a0| <strong>Compulsory Licensing: All parties\u00a0filed Reconsideration Actions against Resolution of Declaration of Public Interest for imatinib (Glivec\u00ae)<\/strong><\/u><\/strong><\/h3>\n<p><span style=\"color: #ffffff;\">\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\">On 12 July 2016, Novartis AG and Novartis de Colombia S.A.\u00a0filed <span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/VS\/MET\/Recurso-Reposicion-Novartis.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">a Reconsideration Action<\/a><\/span> against <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.olartemoure.com\/wp-content\/uploads\/2016\/06\/160617-Glivec-Resolucion-2475-de-2016-MinSalud.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Resolution 2475 (14 June 2016)<\/a><\/span>,\u00a0that (i) issued a Declaration of Public Interest (DPI) against\u00a0imatinib (Glivec\u00ae) and (ii) -instead of ordering a Compulsory License (CL)- it requested the National Pharmaceutical Price Commission (NPPC) to decide a new methodology to determine the price of Glivec\u00ae (\u03b2 polymorph) using generic imatinib prices in reference countries.<\/p>\n<p style=\"text-align: justify;\">On the other hand, the NGOs that initially filed the DPI seeking a CL, filed their <span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/VS\/MET\/Recurso-reposicion-Resimatinib-Ifarma-20160705.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">own Reconsideration Action<\/a><\/span> insisting that a CL should issue.<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>CHILE | Intellectual Property | <strong>Countdown for Chile accepting documents legalized by Apostille<\/strong><\/strong><\/span><\/h3>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\">Starting on\u00a030 August 2016, Chile will accept documents legalized by Apostille. \u00a0On this Date,\u00a0<span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.hcch.net\/en\/instruments\/conventions\/full-text\/?cid=41\" target=\"_blank\" rel=\"noopener noreferrer\">Hague Convention Apostille<\/a><\/span> comes into force in that country.<\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.hcch.net\/en\/instruments\/conventions\/status-table\/?cid=41\" target=\"_blank\" rel=\"noopener noreferrer\">Chile\u2019s accession<\/a><\/span> became final on 16 December 2015, and for now is the latest State to become a Member of the Convention, State No. 112.<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA\u00a0| Patents\u00a0| <strong>Colombian IP Office invites inventors to participate in the National Award to the Colombian Inventor<\/strong><\/strong><\/span><\/h3>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sic.gov.co\/drupal\/recursos_user\/inventor_colombiano_2016\/index.html\" target=\"_blank\" rel=\"noopener noreferrer\">The contest<\/a><\/span> will reward Colombian inventors that with their creations contribute to\u00a0technological, economic and welfare progress.<\/p>\n<p style=\"text-align: justify;\">The Award has 4 categories (i. children, ii. adolescents, iii. research, and iv. industry) and allows natural and legal persons to participate.<\/p>\n<p style=\"text-align: justify;\">Winners will be announced on 1 December 2016 and will receive various\u00a0benefits, including participation in at least one technology fair, partial financing of prosecution stage and the option to <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sic.gov.co\/drupal\/programa-OMPI-FEM-de-asistencia-a-inventores-PAI\" target=\"_blank\" rel=\"noopener noreferrer\">participate in<\/a><\/span> the WIPO-World Economic Forum <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.wipo.int\/iap\/en\" target=\"_blank\" rel=\"noopener noreferrer\">Inventor Assistance Program<\/a><\/span>.<\/p>\n<p style=\"text-align: justify;\">Registration will be open until 9 September 2016. For more information, <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sic.gov.co\/drupal\/recursos_user\/inventor_colombiano_2016\/metodologia.html\" target=\"_blank\" rel=\"noopener noreferrer\">please visit this link<\/a><\/span>.<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">\u00a0<\/span><\/p>\n<h3 style=\"text-align: center;\"><strong><u>COLOMBIA | Patents | <strong>Patent applications filed by Colombian residents increases 95%<\/strong><\/u><\/strong><\/h3>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\">Patent applications filed by Colombian residents during the first semester 2016 surged\u00a0from 127 to 248, compared to the same period of 2015.<\/p>\n<p style=\"text-align: justify;\">Most patents filed by Colombian nationals belong to individuals, followed by the industry and university sectors.\u00a0 As to tech\u00a0sectors, most applications are related to the Mechanical Engineering arts, followed by Chemical\u00a0Processes arts.<\/p>\n<p style=\"text-align: justify;\">The Colombian Patent and Trademark Office considers that -at the end of 2016-, national applicants could file over 500 patent applications, which means that Colombia could for the first time lead the Latin America % share\u00a0of patent applications filed by resident applicants vs. nonresidents by country.<\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sic.gov.co\/drupal\/noticias\/aumentan-solicitudes-de-patentes-de-invencion-nacionales-en-primer-semestre-de-2016\" target=\"_blank\" rel=\"noopener noreferrer\">In this link<\/a>,<\/span>\u00a0you could see more information.<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA, ANDEAN COMMUNITY | Copyright, Unfair Competition\u00a0| <strong>Andean Court of Justice issues Prejudicial Interpretation on lawsuit between Colombian private television channels and pay television distributors<\/strong><\/strong><\/span><\/h3>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\">By means of <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.olartemoure.com\/wp-content\/uploads\/2016\/07\/160728-Interpretacion-Prejudicial-Caracol-y-RCN-vs-Telmex-Telefonica-ETB-DIRECTV-225-IP-2015.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Prejudicial Interpretation 225-IP-2015<\/a><\/span> (issued on 23 June 2016) the Andean Court of Justice\u00a0provided its binding legal opinion in an\u00a0injunction procedure between Colombian private television channels RCN and Caracol -on one hand- versus\u00a0pay TV distributors Telmex, Telef\u00f3nica, DIRECTV and ETB for\u00a0transmitting High-Definition signals without authorization.<\/p>\n<p style=\"text-align: justify;\">The Andean Court considers that a transmission without authorization (except compulsory licenses) involves infringement of broadcaster rights, and may even result in copyright infringement\u00a0if protected content is retransmitted without the owner\u2019s authorization. \u00a0It also considers proper\u00a0the issuance\u00a0of injunctive relief\u00a0by the Colombian IP Office \u2013as the one taken in the referenced case-.<\/p>\n<p style=\"text-align: justify;\">Purpose of Prejudicial\u00a0Interpretations is ensure the uniform\u00a0interpretation of Andean Law in Andean Community countries.\u00a0 The national Judge that resolves the case must apply the Prejudicial Interpretations to the facts of the case.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>. COLOMBIA\u00a0| Patents, Regulatory\u00a0| Compulsory Licensing: All parties\u00a0filed Reconsideration Actions against Resolution of Declaration of Public Interest for imatinib (Glivec\u00ae) \u00a0 On 12 July 2016, Novartis AG and Novartis de Colombia S.A.\u00a0filed a Reconsideration Action against Resolution 2475 (14 June 2016),\u00a0that (i) issued a Declaration of Public Interest (DPI) against\u00a0imatinib (Glivec\u00ae) and (ii) -instead of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6260,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[59],"tags":[],"class_list":["post-5513","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newsletter-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>OM Weekly Digest (29-07-2016) - OlarteMoure | Intellectual Property<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OM Weekly Digest (29-07-2016)\" \/>\n<meta property=\"og:description\" content=\". COLOMBIA\u00a0| Patents, Regulatory\u00a0| Compulsory Licensing: All parties\u00a0filed Reconsideration Actions against Resolution of Declaration of Public Interest for imatinib (Glivec\u00ae) \u00a0 On 12 July 2016, Novartis AG and Novartis de Colombia S.A.\u00a0filed a Reconsideration Action against Resolution 2475 (14 June 2016),\u00a0that (i) issued a Declaration of Public Interest (DPI) against\u00a0imatinib (Glivec\u00ae) and (ii) -instead of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"OlarteMoure | Intellectual Property\" \/>\n<meta property=\"article:published_time\" content=\"2016-07-29T22:21:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-04-26T14:25:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"842\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\"},\"headline\":\"OM Weekly Digest (29-07-2016)\",\"datePublished\":\"2016-07-29T22:21:49+00:00\",\"dateModified\":\"2017-04-26T14:25:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/\"},\"wordCount\":556,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-eng-03.jpg\",\"articleSection\":[\"Newsletter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/\",\"name\":\"OM Weekly Digest (29-07-2016) - OlarteMoure | Intellectual Property\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-eng-03.jpg\",\"datePublished\":\"2016-07-29T22:21:49+00:00\",\"dateModified\":\"2017-04-26T14:25:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/#primaryimage\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-eng-03.jpg\",\"contentUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-eng-03.jpg\",\"width\":\"842\",\"height\":\"482\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-29-07-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OM Weekly Digest (29-07-2016)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/\",\"name\":\"OlarteMoure | Intellectual Property\",\"description\":\"Firma especializada en Propiedad Intelectual\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/olartemoure.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OM Weekly Digest (29-07-2016) - OlarteMoure | Intellectual Property","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/","og_locale":"en_US","og_type":"article","og_title":"OM Weekly Digest (29-07-2016)","og_description":". COLOMBIA\u00a0| Patents, Regulatory\u00a0| Compulsory Licensing: All parties\u00a0filed Reconsideration Actions against Resolution of Declaration of Public Interest for imatinib (Glivec\u00ae) \u00a0 On 12 July 2016, Novartis AG and Novartis de Colombia S.A.\u00a0filed a Reconsideration Action against Resolution 2475 (14 June 2016),\u00a0that (i) issued a Declaration of Public Interest (DPI) against\u00a0imatinib (Glivec\u00ae) and (ii) -instead of [&hellip;]","og_url":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/","og_site_name":"OlarteMoure | Intellectual Property","article_published_time":"2016-07-29T22:21:49+00:00","article_modified_time":"2017-04-26T14:25:07+00:00","og_image":[{"width":842,"height":482,"url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/#article","isPartOf":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/"},"author":{"name":"admin","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807"},"headline":"OM Weekly Digest (29-07-2016)","datePublished":"2016-07-29T22:21:49+00:00","dateModified":"2017-04-26T14:25:07+00:00","mainEntityOfPage":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/"},"wordCount":556,"commentCount":0,"image":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","articleSection":["Newsletter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/","url":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/","name":"OM Weekly Digest (29-07-2016) - OlarteMoure | Intellectual Property","isPartOf":{"@id":"https:\/\/olartemoure.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/#primaryimage"},"image":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","datePublished":"2016-07-29T22:21:49+00:00","dateModified":"2017-04-26T14:25:07+00:00","author":{"@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807"},"breadcrumb":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/#primaryimage","url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","contentUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","width":"842","height":"482"},{"@type":"BreadcrumbList","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-29-07-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/olartemoure.com\/en\/"},{"@type":"ListItem","position":2,"name":"OM Weekly Digest (29-07-2016)"}]},{"@type":"WebSite","@id":"https:\/\/olartemoure.com\/#website","url":"https:\/\/olartemoure.com\/","name":"OlarteMoure | Intellectual Property","description":"Firma especializada en Propiedad Intelectual","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/olartemoure.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/olartemoure.com\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/5513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/comments?post=5513"}],"version-history":[{"count":0,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/5513\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media\/6260"}],"wp:attachment":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media?parent=5513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/categories?post=5513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/tags?post=5513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}